Fig. 3: Relationship between the gut microbiome and clinical efficacy. | Nature Medicine

Fig. 3: Relationship between the gut microbiome and clinical efficacy.

From: Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial

Fig. 3

a–b, Principal coordinate analysis (PCoA) representing β-diversity of baseline versus post-FMT samples in NSCLC (n = 84 samples from n = 19 patients; a) and in melanoma (n = 98 samples from n = 20 patients; b). Group differences in dispersion were assessed and measured using β-diversity dispersion. c–d, LDA using LEfSe representation in NSCLC (n = 65 samples from n = 19 patients; c) and melanoma (n = 79 samples from n = 20 patients; d) after FMT comparing R to NR. Significant values had LDA scores greater than 2 and P < 0.05. e–f, Heatmap representation comparing responders at baseline compared to 1 month after FMT in NSCLC (n = 28 samples from n = 15 patients; e) and melanoma (n = 26 samples from n = 14 patients; f). Bacteria with P < 0.05 according to Wilcoxon test between timepoints are shown in the heatmaps.

Back to article page